Sitemap - 2025 - Biotech Dodo
#77 - Yuletide isotopes, venture stockings, & the hunger helper
#76 - Fungal fowl, fertility failings & Parkinsons in our pipes
#75 – Policy shifts, GLP plateaus, & pattern baldness
#74 - Enzymes, espionage, and experimental excrement
#73 – Superbug Turkeys, Venom Cures and Camel Antibodies
#72 - The real housewives of bidding wars, regulations, and CRISPR
#71 - Gut instincts, artificial wombs, and the UK brain drain
#70 – Trick or treat?! Discount drugs and the secrets of eternal youth
#69 - Collapsing trials, clever pigs & cutthroat exits
#68 – Heatproof bugs, high-yield bonds & herpes vectors
#67 – Assassinations, acquisitions, and autoimmune ambition
#66 – Irish science, cardiac silence, and fibrotic defiance
#65 – Feathered dreams and gene therapy schemes
#64 – Frozen funding, vanishing labs, and stem cells for strokes
#63 – Mind the mitochondria: biotech takes aim at Parkinson’s & ALS
#62 - Mind the mozzies: biotech bites back
#61 - This little piggy had a transplant
#60 - New approvals, new models, new money
#59 - Cell-ebrate good times, come on!
#58 - Choc, stock and two smoking trials
#57 - AI sharpens up, Merck makes cuts & FDA yields
#56 - Spud-tacular developments & starchy standoffs
#55 - Of mice, cats, and medicine
#54 - Moss-powered medicines & the next Moderna
#53 - All aboard the funding flight!
#52 - Hydrogen snacks, metabolic acts & policy quacks
#51 - Genetic wins and ChatGPT biology
#50 - Zombie brains, phage gains & Recursion pains
#49 - Moo-ve over, milk’s got a biotech makeover
#48 - CRISPR twins, criminal grins & clinical crises
#47 - Malaria’s Achilles' heel discovered by scientists
#45 - Research cuts, M&A jitters, and the return of the dire wolf?
#44 - Taco Bell-fueled futures & Merck markdowns
#43 - Brainy breakthroughs and schizophrenia stumbles
#42 - Just drug it? New Nike minds & pharma binds
#41 - Billion Dollar Deals and the Rise of Chinese Biotechs
#40 - Sacked, stacked & stealth-taxed
#39 - Lawsuits, lab launches & deleting your DNA data
#38 - Billion-dollar deals and the end of animal testing
#37 - PrEP, plastic-eating proteins, & a pricey pivot
#36 - Woolly mammoths, billion-euro funds and new cancer breakthroughs
#35 - Risk scores, rare diseases, and ripe tech
#34 - FDA Cutbacks, lymphoma therapies and new AI models
#33 - The Super Bowl, cattle & cosmic experiments
#32 - UK biotech surge, Europe’s new hub & green gains
#31 - Quantum cures, yeast feats & Pfizer drama
#30 - A biotech bounce back, multi-million dollar deals and the Trump effect